TABLE 1.
Demographic and Clinical Data
| Clinical parameters | Huashan parkinsonian PET imaging dataset (Chinese cohort) | German cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Pretraining cohort | Training cohort | Blind-test cohort | ||||||
| Overall | Short symptom duration (≤2 y) | Long symptom duration (>2 y) | Overall | Baseline | Follow-up | |||
| IPD* | ||||||||
| Patient (n) | 241 | 299 | 136 | 163 | 211 | 66 | 66 | 34 |
| Sex (male/female) | 154/87 | 166/133 | 73/63 | 93/70 | 130/81 | 43/23 | 43/23 | 21/13 (34/34) |
| Age at PET (y) | 50.0 ± 15.5 | 60.2 ± 8.5 | 59.1 ± 9.0 | 61.0 ± 8.0 | 60.0 ± 7.6 | 60.0 ± 7.9 | 62.1 ± 7.9 | 72.9 ± 9.5 (34/34) |
| Symptom duration at PET (mo) | – | 45.3 ± 46.0 | 13.0 ± 5.9 | 72.3 ± 47.4 | 39.0 ± 41.3 | 26.0 ± 24.1 | 53.4 ± 24.2 | 44.5 ± 32.9 (18/34) |
| Hoehn and Yahr stage† | – | 2.2 ± 1.0 | 1.7 ± 0.6 | 2.7 ± 1.0 | 1.9 ± 0.9 | 1.6 ± 0.7 | 1.9 ± 0.6 | 1.6 ± 0.8 (22/34) |
| UPDRS III | – | 27.0 ± 14.3 | 18.9 ± 8.9 | 33.8 ± 14.5 | 22.8 ± 12.1 | 19.6 ± 9.1 | 24.2 ± 10.1 | 12.0 ± 3.6 (3/34) |
| Clinical follow-up (mo) | – | – | – | – | 46.8 ± 30.4 | – | 64.5 ± 25.3 | 19.1 ± 21.8 (14/34) |
| MSA* | ||||||||
| Patient (n) (MSA-C/MSA-P) | 79 | 150 (57/93) | 90 (39/51) | 60 (18/42) | 61 (21/40) | 22 (8/14) | 22 (8/14) | 17 (8/8/1) |
| Sex (male/female) | 42/37 | 78/72 | 47/43 | 31/29 | 32/29 | 14/8 | 14/8 | 10/7 (17/17) |
| Age at PET (y) | 57.5 ± 10.6 | 57.8 ± 8.0 | 56.5 ± 8.1 | 59.6 ± 7.4 | 58.5 ± 6.3 | 58.3 ± 7.4 | 60.3 ± 7.3 | 61.3 ± 8.3 (17/17) |
| Symptom duration at PET (mo) | – | 24.3 ± 17.1 | 13.9 ± 6.0 | 39.9 ± 16.5 | 27.0 ± 20.1 | 22.1 ± 11.8 | 45.6 ± 12.5 | 30.0 ± 22.2 (17/17) |
| Hoehn and Yahr stage† | – | 3.1 ± 0.8 | 3.0 ± 0.8 | 3.5 ± 0.7 | 2.9 ± 0.8 | 2.6 ± 0.6 | 3.4 ± 0.8 | 2.4 ± 1.1 (15/17) |
| UPDRS III | – | 30.6 ± 14.5 | 25.9 ± 12.4 | 37.6 ± 14.7 | 29.3 ± 14.4 | 23.5 ± 8.2 | 36.4 ± 11.1 | 34.6 ± 12.8 (11/17) |
| Clinical follow-up (mo) | – | – | – | – | 30.7 ± 18.2 | – | 41.7 ± 16.4 | 22.6 ± 22.4 (17/17) |
| PSP* | ||||||||
| Patient (n) | 78 | 98 | 34 | 64 | 58 | 20 | 20 | 39 |
| Sex (male/female) | 45/33 | 60/38 | 23/11 | 37/27 | 39/19 | 17/3 | 17/3 | 21/18 (39/39) |
| Age at PET (y) | 64.6 ± 8.6 | 67.2 ± 8.0 | 65.0 ± 9.3 | 68.5 ± 6.9 | 65.1 ± 6.6 | 64.8 ± 7.5 | 67.0 ± 7.2 | 70.0 ± 7.1 (39/39) |
| Symptom duration at PET (mo) | – | 35.0 ± 20.7 | 15.3 ± 5.4 | 45.5 ± 18.0 | 34.1 ± 22.7 | 32.4 ± 22.0 | 58.8 ± 22.8 | 22.4 ± 15.7 (37/39) |
| Hoehn and Yahr stage† | – | 3.2 ± 0.8 | 2.9 ± 0.6 | 3.4 ± 0.8 | 3.0 ± 0.8 | 2.7 ± 1.0 | 3.6 ± 0.8 | 2.6 ± 1.1 (37/39) |
| UPDRS III | – | 30.1 ± 13.5 | 28.0 ± 11.0 | 31.2 ± 14.6 | 26.8 ± 11.0 | 23.0 ± 10.4 | 34.6 ± 15.9 | 37.0 ± 15.9 (20/39) |
| Clinical follow-up (mo) | – | – | – | – | 25.1 ± 15.7 | – | 37.5 ± 12.9 | 22.2 ± 13.8 (17/39) |
*
Diagnosis information: Supplemental Table 1.
†
Detailed Hoehn and Yahr stage information: Supplemental Table 2.
Data are shown as mean ± SD. In German cohort, associated numbers of subjects with these items are provided together with statistics information (subject number with certain item/total subject number).
UPDRS = Unified Parkinson’s Disease Rating Scale; MSA-C/MSA-P = MSA-cerebellar/MSA-parkinsonian.